Literature DB >> 15127983

Early diagnosis is key in vancomycin-induced linear IgA bullous dermatosis and Stevens-Johnson syndrome.

Douglas H Jones1, Michael Todd, Timothy J Craig.   

Abstract

BACKGROUND: With the emergence of highly resistant beta-lactam gram-positive organisms, vancomycin hydrochloride usage has increased considerably. Consequently, adverse drug reactions, including unfavorable cutaneous events, have also increased. Important adverse skin reactions are linear IgA bullous dermatosis (LABD) and Stevens-Johnson syndrome (SJS). These blistering disorders can have clinical manifestations that are difficult to distinguish; however, it is important to make the distinction because treatment and prognosis are different.
OBJECTIVE: The purpose of this study is to review the literature on LABD and SJS and compare important differentiating characteristics to assist physicians in making the correct diagnosis.
METHODS: The authors used MEDLINE to search for all published studies on vancomycin adverse events, and combined LABD, SJS, exanthema, and skin rashes each separately with vancomycin adverse events. Furthermore, the authors searched PubMed for all meta-analyses and randomized controlled clinical trials relating to treatment of patients with SJS.
RESULTS: Clinically, LABD and SJS both present similarly with bullae. Diagnosis is made by use of perilesional skin biopsy and direct immunofluorescence. Direct immunofluorescence shows linear IgA deposition along the basement membrane zone in LABD, whereas this is absent in SJS. The treatment for both vancomycin-induced SJS and vancomycin-induced LABD is prompt discontinuation of the drug. However, if SJS is diagnosed early, systemic corticosteroids appear to decrease morbidity.
CONCLUSIONS: In cases of SJS or LABD that are difficult to distinguish clinically, the authors recommend performing a skin biopsy and direct immunofluorescence early to confirm the diagnosis so that effective treatment can be instituted.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15127983

Source DB:  PubMed          Journal:  J Am Osteopath Assoc        ISSN: 0098-6151


  7 in total

1.  A 62-year-old man with new-onset bullae.

Authors:  August J Generoso; Jordana A Goldman; Alan H Wolff
Journal:  Allergy Asthma Proc       Date:  2021-03-01       Impact factor: 2.587

2.  Vancomycin-induced Linear IgA Bullous Dermatosis: A Case Report and Review of the Literature.

Authors:  Min Ju Kang; Hyung Ok Kim; Young Min Park
Journal:  Ann Dermatol       Date:  2008-06-30       Impact factor: 1.444

3.  Stevens-Johnson Syndrome Following Vancomycin and Linezolid: A Real-World Analysis of Post-Marketing Surveillance Data.

Authors:  Ming Ni; Xue-Dong Yin; Wen-Juan Hu; Na Zeng; Bin Zhao; Zhi-Ling Li
Journal:  Front Pharmacol       Date:  2022-04-28       Impact factor: 5.988

4.  Vancomycin-Induced Leukocytoclastic Vasculitis and Acute Renal Failure Due to Tubulointerstitial Nephritis.

Authors:  Chandra Shekar Pingili; Emmanuel E Okon
Journal:  Am J Case Rep       Date:  2017-09-25

5.  A Rare Case of Vancomycin-Induced Linear Immunoglobulin A Bullous Dermatosis.

Authors:  Pinky Jha; Kurtis Swanson; Jeremiah Stromich; Basia M Michalski; Edit Olasz
Journal:  Case Rep Dermatol Med       Date:  2017-01-10

6.  Linear IgA bullous dermatosis: a rare side effect of vancomycin.

Authors:  Pradeep K Selvaraj; Faisal A Khasawneh
Journal:  Ann Saudi Med       Date:  2012-07-01       Impact factor: 1.526

7.  Eosinophil-rich linear IgA bullous dermatosis induced by mRNA COVID-19 booster vaccine.

Authors:  William J Nahm; Michelle Juarez; Julie Wu; Randie H Kim
Journal:  J Cutan Pathol       Date:  2022-08-03       Impact factor: 1.458

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.